|
|
|
|
Vol. 8, Issue 12, 2563-2573, December 1997
and
*Department of Molecular Biology, Princeton University, Princeton,
New Jersey 08544-1014; and
Department of Surgery, Robert
Wood Johnson Medical School, New Brunswick, New Jersey 08903
| |
ABSTRACT |
|---|
|
|
|---|
Initiation of fibronectin (FN) matrix assembly is dependent
on specific interactions between FN and cell surface integrin receptors. Here, we show that de novo FN matrix assembly exhibits a
slow phase during initiation of fibrillogenesis followed by a more
rapid growth phase. Mn2+, which acts by enhancing
integrin function, increased the rate of FN fibril growth, but
only after the initial lag phase. The RGD cell-binding sequence in type
III repeat 10 is an absolute requirement for initiation by
5
1
integrin. To investigate the role of the cell-binding synergy
site in the adjacent repeat III9, a full-length recombinant
FN containing a synergy mutation, FN(syn
), was tested for
its ability to form fibrils. Mutation of this site drastically reduced
FN assembly by CHO
5 cells. Only sparse short fibrils were formed
even after prolonged incubation, indicating that
FN(syn
) is defective in progression of the
assembly process. These results show that the synergy site is essential
for
5
1-mediated accumulation of a FN matrix. However, the
incorporation of FN(syn
) into fibrils and the
deoxycholate-insoluble matrix could be stimulated by Mn2+.
Therefore, exogenous activation of integrin receptors can
overcome the requirement for FN's synergy site as well as modulate the rate of FN matrix formation.
| |
INTRODUCTION |
|---|
|
|
|---|
The interaction of cell surface integrin receptors with
the extracellular matrix plays a critical role in the regulation of a
number of cellular functions including adhesion and migration, cytoskeletal organization, and cell cycle progression (reviewed in
Hynes, 1990
; 1992
; Yamada and Miyamoto, 1995
; Assoian, 1997
). Fibronectin (FN) is an essential extracellular matrix
component as demonstrated by the fact that null mutations in either FN
or its integrin receptors result in embryonic lethality (George
et al., 1993
; reviewed in Fassler et al., 1996
).
Oncogenically transformed cells generally show reduced FN expression,
further supporting a role for the FN matrix in regulating cell
morphology and growth (Yamada et al., 1976
; Ali et
al., 1977
; Giancotti and Ruoslahti, 1990
).
The majority of integrin-mediated interactions with FN
occur through the arg-gly-asp (RGD) cell-binding sequence in repeat III10 (Ruoslahti, 1991
; Hynes, 1992
). For some
integrins, such as
v
3, the RGD sequence alone is
sufficient to support adhesion to FN (Bowditch et al., 1994
;
Danen et al., 1995
). Other integrins, including
5
1 and
IIb
3, require the presence of additional domains
(Aota et al., 1991
; Bowditch et al., 1991
). For
example, adhesion of cells to FN via
5
1 integrin requires
not only the RGD site but a second synergy site corresponding to the
sequence pro-his-ser-arg-asp (PHSRN) in repeat III9 (Aota
et al., 1994
). Both sites are also required for
Xenopus gastrulation, providing additional functional
evidence for the importance of the synergy site (Ramos and DeSimone,
1996
). RGD-mediated adhesion can also be modulated by exogenous
activators. For example, binding of certain antibodies to
integrin extracellular domains can activate the receptors from
a low- to high-affinity state for ligand binding (Frelinger et
al., 1991
; Arroyo et al., 1992
; Kovach et
al., 1992
). Divalent cations such as Mn2+ can also
stimulate integrin activity and interactions with ligand (Gailit and Ruoslahti, 1988
; Bazzoni et al., 1995
; Mould
et al., 1995
; reviewed in Humphries, 1996
; Mould, 1996
).
In addition to its role in cell adhesion, the RGD sequence is also
essential for assembly of FN into a complex fibrillar matrix. Recombinant FNs (recFNs) containing a deletion of the RGD site are
unable to initiate matrix assembly (Sechler et al., 1996
). Furthermore, antibodies to
5
1 integrin or the
cell-binding domain of FN can inhibit assembly (Akiyama et
al., 1989
; Roman et al., 1989
; Fogerty et
al., 1990
; Nagai et al., 1991
). Following
integrin ligation, this multistep assembly process proceeds
through specific interactions between individual FN molecules
culminating in the formation of a detergent-insoluble matrix (McDonald,
1988
; Schwarzbauer, 1991
; Morla and Ruoslahti, 1992; Mosher, 1993
;
Aguirre et al., 1994
; Hocking et al., 1994
). Some
of the interactions during these later stages are RGD independent,
suggesting that integrins might not be involved in all stages
of FN assembly.
Although
5
1 is the major receptor on cells that assemble FN
fibrils, other integrins are also able to participate in this process (Wu et al., 1995
, 1996
; Wennerberg et
al., 1996
; Yang and Hynes, 1996
). For
IIb
3 and
v
3
integrins, efficient assembly is dependent on antibody
activation of the receptors to a high-affinity state for ligand
binding. As
v integrins bind FN via the RGD sequence, this
raises the question whether the synergy site plays a role in any of the
stages of FN assembly.
In this report, we show that the dual interaction of the RGD and
synergy sites with
5
1 integrin is required to fully
support matrix assembly. De novo assembly of FN progressed through a
slow phase of fibril initiation which was followed by a more rapid accumulation of a deoxycholate (DOC)-insoluble matrix. In contrast, assembly of FN(syn
), a recFN containing a mutation in the
synergy site, was stalled during the initiation phase. Exogenous
stimulation of
5
1 function with Mn2+ overcame the
block in assembly of FN(syn
). Mn2+ activation
of
5
1 also affected assembly of FN, resulting in a dramatic
increase in the rate of conversion of fibrils into a DOC-insoluble
matrix. With both native and mutant FNs, the stimulatory effect
occurred only after the assembly of fibrils had been initiated. These
results show that the required levels of integrin activity differ for
5
1-mediated initiation and for accumulation of dense matrix. In the absence of synergy site binding, the latter step can be
induced by exogenous integrin activators. It is also
possible that the assembly of a FN matrix may itself activate
5
1 in an RGD and synergy site-dependent process.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Antibodies and Reagents
Ascites fluid was isolated from the previously described
hybridoma cells producing rat-specific monoclonal antibody IC3 (Sechler et al., 1996
; Sechler and Schwarzbauer, 1997
). The function
blocking antihamster
5 antibody PB1 (Brown and Juliano, 1985
, 1988
)
and function blocking antihuman
5 antibody m16 (Akiyama et
al., 1989
) were kindly provided by R.L. Juliano (University of
North Carolina-Chapel Hill, Chapel Hill, NC) and K. Yamada (National
Institutes of Health, Bethesda, MD), respectively. The activating
anti-
3 antibody LIBS6 (Frelinger et al., 1991
) was
provided by M.H. Ginsberg (Scripps Research Institute, La Jolla, CA).
Fluorescein-conjugated goat anti-mouse IgG was purchased from Molecular
Probes (Eugene, OR). Cycloheximide was purchased from Sigma Chemical
Co. (St. Louis, MO).
Cell Culture
CHO
5 cells, clone 17, transfected with a cDNA to the human
5 integrin subunit have been described previously (Sechler
et al., 1996
; Sechler and Schwarzbauer, 1997
). For all
experiments CHO
5 cells were cultured in DMEM, 2 mM glutamine, 1%
nonessential amino acids, 100 µg/ml Geneticin (Life Technologies,
Grand Island, NY), and 10% fetal calf serum (Hyclone Labs, Logan, UT)
depleted of FN by gelatin-agarose affinity chromatography. The CHO K1
v
3 cell line (described in Wu et al., 1996
) was kindly
provided by M.H. Ginsberg (Scripps Research Institute) and maintained
in DMEM supplemented with 10% fetal calf serum (Hyclone Labs), 2 mM
glutamine, and 1% nonessential amino acids. For immunofluorescence
experiments, FN-depleted fetal calf serum was used.
FN cDNA Construction and Recombinant Protein Purification
Mutation of the synergy site was generated using polymerase
chain reaction (PCR) amplification with a mutant oligonucleotide. The
mutant primer, FNPSR/GSE
(5
-TAGAATTCTCTGAGCCCGGCACTCGG-3
), was
prepared by the Synthesis and Sequencing Facility (Princeton University, Princeton, NJ) and spans nucleotides 4507 to 4482 of the
rat FN cDNA. Base pair changes are underlined and change the codons
from proline to glycine and from arginine to glutamate at amino acid
positions 1498 and 1500, respectively. PCR amplification was performed
using FNPSR/GSE and an upstream primer for 30 cycles under the
following conditions: 95°C, 30 s; 37°C, 60 s; and 72°C, 60 s. The 690-bp product was digested with RsrII and
EcoRI (within the primer) and the resulting 395-bp fragment
was then used to insert the synergy site mutation into the FN cDNA in
pVL1392. The mutation was confirmed following construction by
restriction digests and sequencing.
Creation of recombinant baculovirus and purification of recombinant
protein were performed as described (Aguirre et al., 1994
; Sechler et al., 1996
). For purification of recombinant FN
protein, baculovirus-infected BTI-TN-5B-4 (High Five) insect cells
(Invitrogen Corp., San Diego, CA) were grown in Express Five serum-free
medium (Life Technologies). Rat plasma FN (pFN) and recombinant FN
(recFN) were purified by gelatin agarose chromatography. Approximately 1 mg of recFN was purified from 5 × 107 infected
cells. Since insect cells do not synthesize endogenous FN, recFN
preparations were free of contaminating FN. RecFNs were stored in 10 mM
3-[cyclohexylamino]-1-propanesulfonic acid (pH 11) and 150 mM NaCl at
80°C.
Immunofluorescence
CHO
5 cells were seeded in medium containing FN-depleted serum
onto glass coverslips in 24-well dishes at a concentration of 2.0 × 105 cells/cm2. A nearly confluent monolayer
resulted after an overnight incubation. pFN or FN(syn
)
was added to cells along with fresh medium and incubated for the
specified period of time. Cells were then washed with
phosphate-buffered saline (PBS) and fixed with 3.7% formaldehyde for
15 min at room temperature. Coverslips were washed with PBS and
incubated for 30 min at 37°C with IC3 ascites diluted 1:1000 in PBS
with 2% ovalbumin. Following incubation with IC3, coverslips were
washed with PBS and incubated with fluorescein-conjugated goat
anti-mouse secondary antibody at a concentration of 1:400. After a
final wash with PBS, coverslips were mounted onto microscope slides with FITC-guard (Testog, Inc., Chicago, IL).
CHO K1
v
3 cells were seeded at a concentration of 5 × 105 cells/cm2 onto glass coverslips in a
24-well dish with medium containing FN-depleted fetal calf serum. Cells
were allowed to attach for 1 h, washed with medium containing 20 µg/ml cycloheximide, and incubated with fresh
cycloheximide-containing medium for an additional hour. After another
wash, medium containing 20 µg/ml cycloheximide, 40 µg/ml PB1
antihamster
5 antibody, 300 µg/ml LIBS6 anti-
3-activating antibody, and either 75 µg/ml pFN or FN(syn
) was added
to the cells and incubated for an additional 6 or 22 h.
Cycloheximide treatment decreased the production of endogenous FN to
undetectable levels as determined by labeling with
[35S]methionine and gelatin binding. Immunofluorescence
staining was then performed as described above. Staining was visualized with a Nikon Optiphot-2 microscope using a 40× plan-apochromatic objective, and photography was performed as described in the study by
Schwarzbauer (1991)
.
Isolation, Detection, and Quantitation of DOC-soluble and -insoluble Material
CHO
5 cells were cultured in a 24-well dish as described above
except in the absence of glass coverslips. pFN and
FN(syn
) were incubated with the cells for defined time
periods. After the incubation period, cells were washed with serum-free
DMEM and lysed in 200 µl of DOC lysis buffer (2% DOC, 0.02 M
Tris-HCl, pH 8.8, 2 mM phenylmethylsulfonyl fluoride, 2 mM EDTA, 2 mM
iodoacetic acid, and 2 mM N-ethylmaleimide) per well.
DOC-insoluble material was isolated and aliquots of DOC-soluble and
-insoluble material were separated by SDS-PAGE. Immunodetection and
quantitation were performed as described (Sechler et al.,
1996
) with the exception that IC3 ascites was used at a dilution of
1:10,000. In initial experiments, immunoblots were
developed with chemiluminescent reagents (Pierce, Rockford, IL) and
repeated at least twice. To quantify results, experiments were repeated
in at least two separate trials using 125I-labeled protein
A as described (Sechler et al., 1996
).
Mn2+ Stimulation and Integrin Function Blocking
CHO
5 cells were seeded in a 24-well dish with glass
coverslips (for immunofluorescence experiments) or without coverslips (for biochemical analysis) and incubated overnight. Fresh medium containing MnCl2 and either pFN or FN(syn
)
was then added to the CHO
5 cells and incubated for defined time
periods. Incubations in the presence of 0.1 and 0.2 mM
MnCl2 were performed for up to 16 h, while exposure to
1 mM MnCl2 was limited to a maximum of 4 h.
Anti-integrin function blocking experiments were performed by
adding FN(syn
) to CHO
5 cells and incubating the cells
for 16 h. One millimolar MnCl2 was then added to
culture medium either alone or with 50 µg/ml m16 and 20 µg/ml PB1
anti-
5 antibodies. Immunofluorescence and isolation of DOC-insoluble
and -soluble material was then performed as described above.
| |
RESULTS |
|---|
|
|
|---|
The Synergy Site Is Required for FN Fibril Assembly
A full-length recFN was constructed to contain a PPSRN to PGSEN
mutation in repeat III9 of rat FN in a region corresponding to the human FN PHSRN synergy site (Aota et al., 1994
).
Recombinant protein [FN(syn
)] was generated with the
baculovirus expression system and purified by gelatin-agarose
chromatography. FN(syn
) and native pFN were added to the
culture medium of CHO
5 cells at a concentration of 25 µg/ml and
incubated for the times specified (Figure
1). These cells lack endogenous FN but
will assemble a matrix when provided with exogenous FN (Sechler
et al., 1996
). FN fibrils were then visualized by indirect
immunofluorescence. pFN was assembled into short fibrils by 1 h of
incubation (Figure 1A), and an increase in the density and length of
these fibrils was observed after longer periods of incubation (Figure
1, B and C). In contrast, at least 6 h of incubation were required
to detect any FN(syn
) at the cell surface (Figure 1D). By
16 h, FN(syn
) was assembled into very sparse short
fibrils (Figure 1E), suggesting that mutation of the synergy site
delays the assembly of this recFN. Increasing the concentration of
FN(syn
) to 50 µg/ml also gave a similar
sparse matrix. There was no significant increase in length or number of
fibrils after 48 h of incubation (Figure 1F), demonstrating that
the absence of a synergy site prevents rather than delays assembly.
|
During FN matrix assembly, fibrils are gradually converted from a
DOC-soluble into a DOC-insoluble form. The amount of DOC-insoluble matrix after 16 h of incubation with FN(syn
) was
similar to DOC-insoluble pFN after only 2 h (Figure
2,A and B). Little change was observed in
FN(syn
) accumulation after 16 h. Furthermore, the
amount of FN(syn
) DOC-insoluble matrix was only slightly
greater than that isolated from cells with FN(RGD
)
(Figure 2B). These results show that FN(syn
) is defective
in the initiation and progression of assembly.
|
Activated
v
3 Integrin Supports
FN(syn
) Matrix Assembly
Function blocking anti-
5 integrin antibodies inhibit FN
fibril formation by CHO
5 cells, indicating that the
5
1
integrin is the principle receptor supporting matrix assembly
in these cells (our unpublished observations). However, activated
v
3 and
IIb
3 integrins can also participate in FN
matrix assembly (Wu et al., 1995
, 1996
). Unlike
5
1
which requires both the RGD and synergy sites for maximal cell adhesion
to FN,
v
3 recognizes only the RGD sequence (Bowditch et
al., 1994
; Danen et al., 1995
). Although CHO
5 cells
showed a 50% reduction in adhesion to FN(syn
) compared
with pFN,
v
3-mediated adhesion of CHO-
v
3 cells was not
significantly different. CHO-
v
3 cells were used to determine whether FN(syn
) is capable of forming fibrils. An
anti-
3-activating antibody (LIBS6) was included to enhance
v
3
activity. As shown in Figure 3, when
v
3 integrin was used as the FN receptor,
FN(syn
) and pFN were assembled into comparable matrices
as assessed by both the amount and morphology of fibrils formed.
Therefore, the synergy site is not essential for fibril assembly by
activated
v
3 receptor.
|
Rate of FN Assembly Can Be Increased with the Addition of Mn2+
Activating antibodies can induce high-affinity binding of
integrins to their ligands (O'Toole et al., 1990
;
Faull et al., 1993
). Similarly, divalent cations such as
Mn2+ have been shown to change integrin binding affinity
(Gailit and Ruoslahti, 1988
; Bazzoni et al., 1995
) and
Mn2+ can increase the binding of
5
1 integrin
receptor to fibronectin (Gailit and Ruoslahti, 1988
; Mould et
al., 1995
). To determine whether Mn2+ stimulation of
5
1 integrin can enhance FN assembly, MnCl2
was added to CHO
5 culture medium along with 25 µg/ml pFN. No
noticeable difference in assembly between Mn2+-treated and
untreated cells was observed after 0.5 h of incubation (Figure
4, A and C). However, by 4 h, the
pFN matrix assembled by Mn2+-treated cells
appeared to be more dense than that of untreated cells (Figure 4, B and
D). Wild-type recFN (FNA
B
; Sechler et
al., 1996
) showed the same Mn2+-stimulated increase in
matrix assembly as pFN. The presence of Mn2+ was not
required for the entire 4-h incubation. A matrix comparable to that
shown in Figure 4D was assembled when Mn2+ was added 2 h after pFN and incubated for 2 additional h.
|
De novo FN assembly into DOC-insoluble matrix follows a
pattern similar to formation of a linear polymer with a slow initiation phase followed by a more rapid growth phase. In untreated CHO
5 cells, the accumulation of total cell-associated FN increased steadily
over time in direct proportion to the input FN concentration (Figure
5A). Incorporation into DOC-insoluble
matrix, however, occurred slowly at early times but showed an increase
after a lag period of several hours (Figure 5B). The initiation phase is more clearly evident with the addition of Mn2+ which
accelerated total FN binding and incorporation into DOC-insoluble material after 2 h but had no apparent effect before that time (Figure 5B). Mn2+ stimulation had a more dramatic effect on
the proportion of DOC-insoluble FN. More than 80% of the total FN was
DOC insoluble with Mn2+ as compared with 35% without
Mn2+ (Figure 5C). Therefore, Mn2+ speeds up the
conversion from DOC-soluble to DOC-insoluble matrix. This is not simply
due to an increase in the amount of FN bound to the cell surface
because doubling the FN concentration did not significantly increase
the proportion of DOC-insoluble matrix.
|
Mn2+ Activation of
5
1 Allows Assembly of
FN(syn
)
An initiation phase of several hours is observed before
significant conversion of FN fibrils into DOC-insoluble matrix.
FN(syn
) appears to be arrested in this phase, since
little DOC-insoluble material is recovered even after prolonged
incubation (see Figure 2). Because Mn2+ can increase matrix
accumulation of pFN by CHO
5 cells, we tested its effects on
FN(syn
) assembly. Incubation for up to 4 h in the
presence of 1 mM MnCl2 did not increase incorporation of
FN(syn
) into fibrils or DOC-insoluble material. However,
a longer 16-h incubation with 0.2 mM MnCl2 did stimulate
assembly of FN(syn
) into a fibrillar matrix (Figure
6). Apparently, Mn2+ cannot
exert an effect on FN(syn
) assembly until significantly
later due to the extended initiation phase observed with the mutant
protein.
|
To test the effects of Mn2+ after initiation of
FN(syn
) fibril assembly, 1 mM MnCl2
was added to CHO
5 cells that had already formed sparse fibrils of
FN(syn
). A substantial increase in the amount of
fibrillar FN(syn
) was evident after only 4 h of
incubation with Mn2+ (Figure
7A). The increase in fibrillar
FN(syn
) also corresponded to a significant accumulation
of DOC-insoluble material (Figure 7B). Mn2+ stimulation
failed to enhance the assembly of FN(RGD
) into
a matrix.
|
To confirm that
5
1 is responsible for Mn2+
stimulation of FN(syn
) matrix assembly, function blocking
anti-integrin antibodies and 1 mM MnCl2 were added
simultaneously to CHO
5 cells with FN(syn
) matrix. As
shown in Figure 8, antihuman and
antihamster
5 integrin antibodies inhibited
FN(syn
) matrix formation. Together, these results
demonstrate that the block in progression of FN(syn
)
matrix assembly can be reversed by altering
5
1 integrin
affinity by Mn2+ stimulation.
|
PMA Does Not Stimulate FN Matrix Assembly by CHO
5 Cells
Other agents such as phorbol esters have been shown to increase
cell adhesion (Danilov and Juliano, 1989
; Vuori and Ruoslahti, 1993
;
Faull et al., 1994
) and matrix assembly (Somers and Mosher, 1993
) by integrin receptors. Phorbol 12-myristate 13-acetate
(PMA) increases cell adhesion to FN without inducing an increase
in the affinity of integrin receptors for ligand (Faull
et al., 1994
). Although treatment of CHO
5 cells with PMA
resulted in an increase in cell spreading (our unpublished
observations), it had no effect on the assembly of pFN into fibrils
(Figure 9,A and B). PMA was also unable
to enhance the incorporation of FN(syn
) into a
matrix (Figure 9C). Furthermore, addition of Mn2+ and PMA
together did not result in an increase in stimulation over
Mn2+ alone. Therefore, agents which alter integrin
function without modulating affinity do not affect matrix assembly in
this system.
|
| |
DISCUSSION |
|---|
|
|
|---|
These analyses provide new insights into the process of FN
assembly into a fibrillar matrix. First, FN assembly into DOC-insoluble matrix begins with a slow initiation phase followed by a more rapid
accumulation phase. This biphasic process is very similar to the
nucleation and growth phases during assembly of linear polymers such as
actin filaments. Second, Mn2+ activation of
integrins does not increase the amount of FN binding during the
initiation phase but instead increases the rate of subsequent matrix
growth, suggesting that a higher level of integrin activation
is required during the later stages of the assembly process. Third,
5
1-mediated assembly is dependent on the presence of the synergy
site and, as we showed previously, also requires the RGD sequence.
Fourth, integrins activated by external agents such as
antibodies or Mn2+ are able to assemble FN without the need
for a synergy site. Together, our results demonstrate that FN assembly
proceeds through at least two different stages and each stage has
different requirements for integrin activation state and FN
sequences. Initially, integrins bind sufficient FN for fibril
formation to begin. Later in the process, the level of integrin
activation determines the rate of accumulation of a dense,
DOC-insoluble matrix. The synergy site is required in this second phase
where contact with the receptor may serve to enhance integrin
activity.
Ligand binding induces a conformational change in the extracellular
domain of integrin receptors, and this change is linked to an
alteration in receptor activity (reviewed in Ginsberg et al., 1992
; Humphries, 1996
; Mould, 1996
). Mn2+ also
alters the conformation of integrins (Bazzoni et
al., 1995
; Humphries, 1996
) and promotes high levels of ligand
binding (Gailit and Ruoslahti, 1988
; Mould et al., 1995
).
Bazzoni et al. (1995)
have shown that the anti-
1 antibody
9EG7 recognizes an epitope which is induced on the integrin
upon binding to ligand or stimulation with Mn2+. This
observation suggests that Mn2+ increases the rate of
conversion of FN to DOC-insoluble matrix and enhances assembly of
FN(syn
) by stabilizing a more active
5
1
integrin conformation. Although Mn2+ can
significantly increase the rate of FN assembly, the effect does not
occur immediately. With both native FN and FN(syn
),
enhancement of matrix assembly only occurred after fibril formation had
been initiated. One interpretation of these results is that initiation
of assembly has different integrin activation requirements than
accumulation into DOC-insoluble matrix. Mn2+ may induce an
integrin conformation particularly favorable for this later
stage. Mn2+ is probably not acting by allowing
5
1
interactions with the mutant synergy site since synergy site activity
is dependent on the arginine residue (Aota et al., 1994
)
which in our mutation has been changed to a glutamate.
FN(syn
) assembly differs from that of
FN(RGD
). A minimal matrix consisting of short sparse
fibrils of FN(syn
) could be detected with both CHO
5
cells as well as At-T20
5 cells (our unpublished observations). The
initiation step was slowed considerably and progression beyond that
phase was prevented. FN(RGD
), in contrast, was
not assembled (Sechler et al., 1996
). In addition, Mn2+ was able to stimulate FN(syn
)
assembly but had no effect on FN(RGD
). Therefore, under
certain conditions it may be possible to make a matrix without a
synergy site but not without an RGD sequence. A dual requirement for
both the synergy site and the RGD sequence in matrix assembly is also
consistent with the results of Nagai et al. (1991)
who
showed that monoclonal anti-FN antibodies that map near the RGD or
synergy sites inhibited the formation of a FN matrix.
Not all agents that stimulate cell adhesion can affect matrix assembly.
Treatment of CHO
5 cells with PMA did not alter the assembly of
either FN or FN(syn
) matrix. In contrast, PMA did
increase
5
1-mediated adhesion to FN fragments lacking a synergy
site (Danen et al., 1995
). Adhesion to these fragments was
maximal when cells were treated with a combination of activating
antibodies, Mn2+, and PMA. Therefore, the requirements for
cell adhesion are different from the requirements for FN matrix
assembly. PMA was not able to induce exposure of the 9EG7 epitope in
5
1 integrin, indicating that the conformational change in
response to Mn2+ stimulation is not induced by PMA (Bazzoni
et al., 1995
). PMA has been shown to affect the binding of
125I-labeled FN to fibroblasts with an established FN
matrix (Somers and Mosher, 1993
) which may be representative of the
later stages of assembly. Our data show that PMA does not influence the
early events of assembly initiation and accumulation but do not rule out the possibility that it could modulate later stages of fibril formation.
We have recently proposed a model for FN matrix assembly in which FN is
converted from an inactive form in solution to an active form at the
cell surface (Sechler et al., 1996
). In this model, FN is
activated for assembly by binding to integin receptors, thus exposing
sites required for the FN-FN interactions needed for fibril formation.
Consistent with this model, Ugarova et al. (1995)
have
demonstrated the presence of reversible conformational states within FN
fragments containing the cell-binding domain. Different epitopes were
exposed depending on whether the fragment was in a "compact" or
"extended" form. This type of regulation is not unique to FN. The
focal adhesion protein vinculin, for example, has been shown to undergo
changes in its conformation which serve to expose ligand-binding sites
(reviewed in Jockusch and Rudiger, 1996
). The results presented in this
report show that, along with FN, integrins also play a dynamic
role in multiple stages of matrix assembly. During initiation,
integrin-FN binding and receptor clustering provide a nucleus
of activated FNs (Figure 10A). As in
other polymerization reactions, this phase is slow. Ligation of FN by
5
1 may induce the appropriate conformational changes within the
integrin to stabilize the interaction and allow accumulation of
additional FN dimers and conversion to DOC-insoluble matrix (Figure
10B). This step can be accelerated by stimulating the integrins
with Mn2+. In the absence of the synergy site, the RGD
region alone is sufficient for some initial binding but the assembly
process becomes stalled, which explains the extended lag phase observed
with the mutant protein. Mn2+ apparently induces a
conformation that further activates
5
1 and allows the assembly of
FN(syn
) to proceed (Figure 10C).
|
Until recently, only
5
1 integrin had been reported to
function in initiating the formation of a FN matrix. However,
5-null and
1-null cells assemble a FN matrix, indicating that other receptors must be able to compensate for the loss of
5
1 (Yang et al., 1993
; Wennerberg et al., 1996
; Yang and
Hynes, 1996
).
IIb
3 and
v
3 integins have been shown to
initiate and sustain FN fibril polymerization in transfected cell lines
(Wu et al., 1995
, 1996
; this report). However, these
integrins require exogenous activation by antibodies to achieve
maximal matrix incorporation. FN assembly by antibody-activated
3
integrins is similar to FN(syn
) assembly by
Mn2+-stimulated
5
1. Neither process requires the
synergy site but both are dependent on exogenous activators.
Apparently, the unique interaction between the synergy-RGD sites of FN
and
5
1 integrin is designed to be particularly favorable
for the polymerization of fibrils.
We have shown that the ability of
5
1 integrin to support
FN matrix assembly is dependent on the presence of both the RGD sequence and the synergy site. Mn2+ activation of
5
1
speeds up the conversion from DOC-soluble to -insoluble matrix and
abrogates the need for a synergy site. The Mn2+ effect is
not seen until the formation of fibrils has been initiated, indicating
that the affinity requirements of FN-
5
1 interactions change
during the later stages of assembly.
| |
ACKNOWLEDGMENTS |
|---|
We thank Drs. Ken Yamada and Rudy Juliano for their kind gifts
of anti-integrin antibodies and Dr. Mark Ginsberg for
generously providing CHO
v
3 cells and LIBS6-activating antibody.
We are grateful to Jen Luczak and Mike Fitzgerald for excellent
technical assistance and to Dr. Saw Kyin of the Departmental DNA
Synthesis/Sequencing facility for preparation of oligonucleotides. This
research was supported by National Institutes of Health grant CA44627
(to J.E.S.). J.L.S. was supported by a postdoctoral fellowship from the
New Jersey Commission on Cancer Research and S.A.C. is an American Heart Association-Genentech Clinician Scientist Awardee.
| |
FOOTNOTES |
|---|
Abbreviations used: DOC, deoxycholate; FN, fibronectin;
FN(RGD
), recombinant FN lacking the RGD
cell-binding sequence; FN(syn
), recombinant FN with
mutation of the synergy site; pFN, plasma fibronectin; recFN,
recombinant FN; PMA, phorbol 12-myristate 13-acetate.
| |
REFERENCES |
|---|
|
|
|---|
1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium.
J. Biol. Chem.
270, 25570-25577
IIIb
3 (platelet GPIIIb-IIIa) recognizes multiple sites in fibronectin.
J. Biol. Chem.
266, 23323-23328
3 integrins.
J. Biol. Chem.
269, 10856-10863
and
subunits of the fibronectin receptor.
Exp. Cell Res.
177, 303-318[Medline].
5
1.
J. Biol. Chem.
270, 21612-21618
5
1: regulation of the functional response by soluble fibronectin.
J. Cell Biol.
121, 155-162
IIb
3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function.
J. Biol. Chem.
266, 17106-17111
5
1 fibronectin receptor suppress the transformed phenotype of the Chinese hamster ovary cells.
Cell
60, 849-859[Medline].
5
1-fibronectin interactions by divalent cations.
J. Biol. Chem.
270, 26270-26277
5
1 integrin-mediated cell spreading on fibronectin.
J. Biol. Chem.
268, 21459-21462
1 integrin-dependent and -independent polymerization of fibronectin.
J. Cell Biol.
132, 227-238
5 integrin-deficient mice.
Development
119, 1093-1105[Abstract].
5
1 integrin can be replaced by
v integrins.
Mol. Biol. Cell
7, 1737-1748[Abstract].
This article has been cited by other articles:
![]() |
|